Toward understanding Machado-Joseph disease

Progress in Neurobiology

Volumn 97, Issue 2, 2012, Pages 239-257

  Costa, Maria do Carmo ^a   Paulson, Henry L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Ataxin 3; Deubiquitinating enzyme; Neurodegeneration; Polyglutamine disease; Protein quality control; Spinocerebellar ataxia

Indexed keywords

ATAXIN 3; DYNEIN ADENOSINE TRIPHOSPHATASE; HEAT SHOCK TRANSCRIPTION FACTOR 1; HISTONE DEACETYLASE 6; LOCKED NUCLEIC ACID; PARKIN; PEPTIDE NUCLEIC ACID; POLYGLUTAMINE; TANESPIMYCIN; TEMSIROLIMUS; UBIQUITIN;

ATAXIA; BASAL GANGLION; BRADYKINESIA; CAG REPEAT; CELL AGING; CELL DIFFERENTIATION; CELL STRESS; CYTOSKELETON; DOWN REGULATION; DROSOPHILA; DYSARTHRIA; DYSPHAGIA; DYSTONIA; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; MACHADO JOSEPH DISEASE; MEDULLA OBLONGATA; MUSCLE ATROPHY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; RIGIDITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANTIA NIGRA; UBIQUITINATION;

ANIMALS; ENDOPEPTIDASES; HUMANS; MACHADO-JOSEPH DISEASE; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PEPTIDES; REPRESSOR PROTEINS;

EID: 84860660444     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.11.006     Document Type: Review

References (240)

1. Abe Y., Tanaka F., Matsumoto M., Doyu M., Hirayama M., Kachi T., Sobue G. CAG repeat number correlates with the rate of brainstem and cerebellar atrophy in Machado-Joseph disease. Neurology 1998, 51:882-884.
2. Alves S., Nascimento-Ferreira I., Auregan G., Hassig R., Dufour N., Brouillet E., Pedroso de Lima M.C., Hantraye P., Pereira de Almeida L., Deglon N. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008, 3:e3341.
3. Alves S., Nascimento-Ferreira I., Dufour N., Hassig R., Auregan G., Nobrega C., Brouillet E., Hantraye P., Pedroso de Lima M.C., Deglon N., de Almeida L.P. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?. Hum. Mol. Genet. 2010, 19:2380-2394.
4. Alves S., Regulier E., Nascimento-Ferreira I., Hassig R., Dufour N., Koeppen A., Carvalho A.L., Simoes S., de Lima M.C., Brouillet E., Gould V.C., Deglon N., de Almeida L.P. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum. Mol. Genet. 2008, 17:2071-2083.
5. Antony P.M., Mantele S., Mollenkopf P., Boy J., Kehlenbach R.H., Riess O., Schmidt T. Identification and functional dissection of localization signals within ataxin-3. Neurobiol. Dis. 2009, 36:280-292.
6. Araujo J., Breuer P., Dieringer S., Krauss S., Dorn S., Zimmermann K., Pfeifer A., Klockgether T., Wuellner U., Evert B.O. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Hum. Mol. Genet. 2011, 20:2928-2941.
7. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 2009, 110:1737-1765.
8. Bauer P.O., Wong H.K., Oyama F., Goswami A., Okuno M., Kino Y., Miyazaki H., Nukina N. Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J. Biol. Chem. 2009, 284:13153-13164.
9. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., Schmitt I., Wullner U., Evert B.O., O'Kane C.J., Rubinsztein D.C. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006, 15:433-442.
10. Berke S.J., Chai Y., Marrs G.L., Wen H., Paulson H.L. Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J. Biol. Chem. 2005, 280:32026-32034.
11. Berke S.J., Paulson H.L. Protein aggregation and the ubiquitin proteasome pathway: gaining the upper hand on neurodegeneration. Curr. Opin. Genet. Dev. 2003, 13:253-261.
12. Berke S.J., Schmied F.A., Brunt E.R., Ellerby L.M., Paulson H.L. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J. Neurochem. 2004, 89:908-918.
13. Bettencourt C., Lima M. Machado-Joseph disease: from first descriptions to new perspectives. Orphanet J. Rare Dis. 2011, 6:35.
14. Bettencourt C., Santos C., Montiel R., Costa M.C., Cruz-Morales P., Santos L.R., Simoes N., Kay T., Vasconcelos J., Maciel P., Lima M. Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3). Neurogenetics 2010, 11:193-202.
15. Bichelmeier U., Schmidt T., Hubener J., Boy J., Ruttiger L., Habig K., Poths S., Bonin M., Knipper M., Schmidt W.J., Wilbertz J., Wolburg H., Laccone F., Riess O. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J. Neurosci. 2007, 27:7418-7428.
16. Bilen J., Bonini N.M. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet. 2007, 3:1950-1964.
17. Boeddrich A., Gaumer S., Haacke A., Tzvetkov N., Albrecht M., Evert B.O., Muller E.C., Lurz R., Breuer P., Schugardt N., Plassmann S., Xu K., Warrick J.M., Suopanki J., Wullner U., Frank R., Hartl U.F., Bonini N.M., Wanker E.E. An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J. 2006, 25:1547-1558.
18. Boy J., Schmidt T., Schumann U., Grasshoff U., Unser S., Holzmann C., Schmitt I., Karl T., Laccone F., Wolburg H., Ibrahim S., Riess O. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol. Dis. 2010, 37:284-293.
19. Boy J., Schmidt T., Wolburg H., Mack A., Nuber S., Bottcher M., Schmitt I., Holzmann C., Zimmermann F., Servadio A., Riess O. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum. Mol. Genet. 2009, 18:4282-4295.
20. Breuer P., Haacke A., Evert B.O., Wullner U. Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control. J. Biol. Chem. 2010, 285:6532-6537.
21. Burk K., Globas C., Bosch S., Klockgether T., Zuhlke C., Daum I., Dichgans J. Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. J. Neurol. 2003, 250:207-211.
22. Burnett B., Li F., Pittman R.N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 2003, 12:3195-3205.
23. Burnett B.G., Pittman R.N. The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4330-4335.
24. Carra S., Boncoraglio A., Kanon B., Brunsting J.F., Minoia M., Rana A., Vos M.J., Seidel K., Sibon O.C., Kampinga H.H. Identification of the Drosophila ortholog of HSPB8: implication of HSPB8 loss of function in protein folding diseases. J. Biol. Chem. 2010, 285:37811-37822.
25. Carvalho D.R., La Rocque-Ferreira A., Rizzo I.M., Imamura E.U., Speck-Martins C.E. Homozygosity enhances severity in spinocerebellar ataxia type 3. Pediatr. Neurol. 2008, 38:296-299.
26. Cemal C.K., Carroll C.J., Lawrence L., Lowrie M.B., Ruddle P., Al-Mahdawi S., King R.H., Pook M.A., Huxley C., Chamberlain S. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum. Mol. Genet. 2002, 11:1075-1094.
27. Chai Y., Berke S.S., Cohen R.E., Paulson H.L. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J. Biol. Chem. 2004, 279:3605-3611.
28. Chai Y., Koppenhafer S.L., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 1999, 19:10338-10347.
29. Chai Y., Koppenhafer S.L., Shoesmith S.J., Perez M.K., Paulson H.L. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 1999, 8:673-682.
30. Chai Y., Shao J., Miller V.M., Williams A., Paulson H.L. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9310-9315.
31. Chai Y., Wu L., Griffin J.D., Paulson H.L. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J. Biol. Chem. 2001, 276:44889-44897.
32. Chang W.H., Tien C.L., Chen T.J., Nukina N., Hsieh M. Decreased protein synthesis of Hsp27 associated with cellular toxicity in a cell model of Machado-Joseph disease. Neurosci. Lett. 2009, 454:152-156.
33. Chen X., Tang T.S., Tu H., Nelson O., Pook M., Hammer R., Nukina N., Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 2008, 28:12713-12724.
34. Chou A.H., Chen S.Y., Yeh T.H., Weng Y.H., Wang H.L. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol. Dis. 2010, 41:481-488.
35. Chou A.H., Yeh T.H., Ouyang P., Chen Y.L., Chen S.Y., Wang H.L. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol. Dis. 2008, 31:89-101.
36. Colomer Gould V.F., Goti D., Pearce D., Gonzalez G.A., Gao H., Bermudez de Leon M., Jenkins N.A., Copeland N.G., Ross C.A., Brown D.R. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol. Dis. 2007, 27:362-369.
37. Costa M.C., Gomes-da-Silva J., Miranda C.J., Sequeiros J., Santos M.M., Maciel P. Genomic structure, promoter activity, and developmental expression of the mouse homologue of the Machado-Joseph disease (MJD) gene. Genomics 2004, 84:361-373.
38. Coutinho P., Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 1978, 28:703-709.
39. Coutinho P., Sequeiros J. [Clinical, genetic and pathological aspects of Machado-Joseph disease]. J. Genet. Hum. 1981, 29:203-209.
40. D'Abreu A., Franca M.C., Yasuda C.L., Campos B.A., Lopes-Cendes I., Cendes F. Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study. J. Neuroimaging 2011, 10.1111/j.1552-6569.2011.00614.x.
41. D'Abreu A., Franca M., Appenzeller S., Lopes-Cendes I., Cendes F. Axonal dysfunction in the deep white matter in Machado-Joseph disease. J. Neuroimaging 2009, 19:9-12.
42. D'Abreu A., Franca M.C., Yasuda C.L., Souza M.S., Lopes-Cendes I., Cendes F. Thalamic volume and dystonia in Machado-Joseph disease. J. Neuroimaging 2010, 21:e91-e93.
43. De Oliveira M.S., D'Abreu A., Franca M.C., Lopes-Cendes I., Cendes F., Castellano G. MRI-texture analysis of corpus callosum, thalamus, putamen, and caudate in Machado-Joseph disease. J. Neuroimaging 2010, 10.1111/j.1552-6569.2010.00553.x.
44. Di Prospero N.A., Fischbeck K.H. Therapeutics development for triplet repeat expansion diseases. Nat. Rev. Genet. 2005, 6:756-765.
45. do Carmo Costa M., Bajanca F., Rodrigues A.J., Tome R.J., Corthals G., Macedo-Ribeiro S., Paulson H.L., Logarinho E., Maciel P. Ataxin-3 plays a role in mouse myogenic differentiation through regulation of integrin subunit levels. PLoS One 2010, 5:e11728.
46. Donaldson K.M., Li W., Ching K.A., Batalov S., Tsai C.C., Joazeiro C.A. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8892-8897.
47. Doss-Pepe E.W., Stenroos E.S., Johnson W.G., Madura K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol. Cell. Biol. 2003, 23:6469-6483.
48. Durcan T.M., Kontogiannea M., Thorarinsdottir T., Fallon L., Williams A.J., Djarmati A., Fantaneanu T., Paulson H.L., Fon E.A. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Hum. Mol. Genet. 2010, 20:141-154.
49. Durr A., Stevanin G., Cancel G., Duyckaerts C., Abbas N., Didierjean O., Chneiweiss H., Benomar A., Lyon-Caen O., Julien J., Serdaru M., Penet C., Agid Y., Brice A. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann. Neurol. 1996, 39:490-499.
50. Eichler L., Bellenberg B., Hahn H.K., Koster O., Schols L., Lukas C. Quantitative assessment of brain stem and cerebellar atrophy in spinocerebellar ataxia types 3 and 6: impact on clinical status. AJNR Am. J. Neuroradiol. 2011, 32:890-897.
51. Ellisdon A.M., Pearce M.C., Bottomley S.P. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J. Mol. Biol. 2007, 368:595-605.
52. Ellisdon A.M., Thomas B., Bottomley S.P. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J. Biol. Chem. 2006, 281:16888-16896.
53. Emmel V.E., Alonso I., Jardim L.B., Saraiva-Pereira M.L., Sequeiros J. Does DNA methylation in the promoter region of the ATXN3 gene modify age at onset in MJD (SCA3) patients?. Clin. Genet. 2011, 79:100-102.
54. Etchebehere E.C., Cendes F., Lopes-Cendes I., Pereira J.A., Lima M.C., Sansana C.R., Silva C.A., Camargo M.F., Santos A.O., Ramos C.D., Camargo E.E. Brain single-photon emission computed tomography and magnetic resonance imaging in Machado-Joseph disease. Arch. Neurol. 2001, 58:1257-1263.
55. Eto K., Sumi S.M., Bird T.D., McEvoy-Bush T., Boehnke M., Schellenberg G. Family with dominantly inherited ataxia, amyotrophy, and peripheral sensory loss. Spinopontine atrophy or Machado-Joseph Azorean disease in another non-Portuguese family?. Arch. Neurol. 1990, 47:968-974.
56. Evert B.O., Araujo J., Vieira-Saecker A.M., de Vos R.A., Harendza S., Klockgether T., Wullner U. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci. 2006, 26:11474-11486.
57. Evert B.O., Vogt I.R., Kindermann C., Ozimek L., de Vos R.A., Brunt E.R., Schmitt I., Klockgether T., Wullner U. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains. J. Neurosci. 2001, 21:5389-5396.
58. Evert B.O., Vogt I.R., Vieira-Saecker A.M., Ozimek L., de Vos R.A., Brunt E.R., Klockgether T., Wullner U. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J. Neuropathol. Exp. Neurol. 2003, 62:1006-1018.
59. Evert B.O., Wullner U., Schulz J.B., Weller M., Groscurth P., Trottier Y., Brice A., Klockgether T. High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Hum. Mol. Genet. 1999, 8:1169-1176.
60. Fei E., Jia N., Zhang T., Ma X., Wang H., Liu C., Zhang W., Ding L., Nukina N., Wang G. Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3. Biochem. Biophys. Res. Commun. 2007, 357:487-492.
61. Ferro A., Carvalho A.L., Teixeira-Castro A., Almeida C., Tome R.J., Cortes L., Rodrigues A.J., Logarinho E., Sequeiros J., Macedo-Ribeiro S., Maciel P. NEDD8: a new ataxin-3 interactor. Biochim. Biophys. Acta 2007, 1773:1619-1627.
62. Fujikake N., Nagai Y., Popiel H.A., Okamoto Y., Yamaguchi M., Toda T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem. 2008, 283:26188-26197.
63. Fukutake T., Shinotoh H., Nishino H., Ichikawa Y., Goto J., Kanazawa I., Hattori T. Homozygous Machado-Joseph disease presenting as REM sleep behaviour disorder and prominent psychiatric symptoms. Eur. J. Neurol. 2002, 9:97-100.
64. Gales L., Cortes L., Almeida C., Melo C.V., Costa M.C., Maciel P., Clarke D.T., Damas A.M., Macedo-Ribeiro S. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3. J. Mol. Biol. 2005, 353:642-654.
65. Gaspar C., Lopes-Cendes I., Hayes S., Goto J., Arvidsson K., Dias A., Silveira I., Maciel P., Coutinho P., Lima M., Zhou Y.X., Soong B.W., Watanabe M., Giunti P., Stevanin G., Riess O., Sasaki H., Hsieh M., Nicholson G.A., Brunt E., Higgins J.J., Lauritzen M., Tranebjaerg L., Volpini V., Wood N., Ranum L., Tsuji S., Brice A., Sequeiros J., Rouleau G.A. Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am. J. Hum. Genet. 2001, 68:523-528.
66. Gispert S., Twells R., Orozco G., Brice A., Weber J., Heredero L., Scheufler K., Riley B., Allotey R., Nothers C., et al. Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat. Genet. 1993, 4:295-299.
67. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 2002, 82:373-428.
68. Goti D., Katzen S.M., Mez J., Kurtis J., Kiluk J., Ben-Haïem L., Jenkins N.A., Copeland N.G., Kakizuka A., Sharp A.H., Ross C.A., Mouton P.R., Colomer V. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J. Neurosci. 2004, 24:10266-10279.
69. Goto J., Watanabe M., Ichikawa Y., Yee S.B., Ihara N., Endo K., Igarashi S., Takiyama Y., Gaspar C., Maciel P., Tsuji S., Rouleau G.A., Kanazawa I. Machado-Joseph disease gene products carrying different carboxyl termini. Neurosci. Res. 1997, 28:373-377.
70. Gu W., Ma H., Wang K., Jin M., Zhou Y., Liu X., Wang G., Shen Y. The shortest expanded allele of the MJD1 gene in a Chinese MJD kindred with autonomic dysfunction. Eur. Neurol. 2004, 52:107-111.
71. Gunawardena S., Goldstein L.S. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch. Neurol. 2005, 62:46-51.
72. Haacke A., Broadley S.A., Boteva R., Tzvetkov N., Hartl F.U., Breuer P. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum. Mol. Genet. 2006, 15:555-568.
73. Haacke A., Hartl F.U., Breuer P. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J. Biol. Chem. 2007, 282:18851-18856.
74. Haberhausen G., Damian M.S., Leweke F., Muller U. Spinocerebellar ataxia, type 3 (SCA3) is genetically identical to Machado-Joseph disease (MJD). J. Neurol. Sci. 1995, 132:71-75.
75. Harris G.M., Dodelzon K., Gong L., Gonzalez-Alegre P., Paulson H.L. Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One 2010, 5:e13695.
76. Hayashi M., Kobayashi K., Furuta H. Immunohistochemical study of neuronal intranuclear and cytoplasmic inclusions in Machado-Joseph disease. Psychiatry Clin. Neurosci. 2003, 57:205-213.
77. Healton E.B., Brust J.C., Kerr D.L., Resor S., Penn A. Presumably Azorean disease in a presumably non-Portuguese family. Neurology 1980, 30:1084-1089.
78. Heir R., Ablasou C., Dumontier E., Elliott M., Fagotto-Kaufmann C., Bedford F.K. The UBL domain of PLIC-1 regulates aggresome formation. EMBO Rep. 2006, 7:1252-1258.
79. Higgins J.J., Nee L.E., Vasconcelos O., Ide S.E., Lavedan C., Goldfarb L.G., Polymeropoulos M.H. Mutations in American families with spinocerebellar ataxia (SCA) type 3: SCA3 is allelic to Machado-Joseph disease. Neurology 1996, 46:208-213.
80. Horimoto Y., Matsumoto M., Yuasa H., Kojima A., Nokura K., Katada E., Yamamoto T., Yamamoto H., Mitake S. Brainstem in Machado-Joseph disease: atrophy or small size?. Eur. J. Neurol. 2008, 15:102-105.
81. Hu J., Gagnon K.T., Liu J., Watts J.K., Syeda-Nawaz J., Bennett C.F., Swayze E.E., Randolph J., Chattopadhyaya J., Corey D.R. Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol. Chem. 2011, 392:315-325.
82. Hu J., Matsui M., Gagnon K.T., Schwartz J.C., Gabillet S., Arar K., Wu J., Bezprozvanny I., Corey D.R. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 2009, 27:478-484.
83. Hubener J., Riess O. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models. Neurobiol. Dis. 2010, 38:116-124.
84. Huen N.Y., Chan H.Y. Dynamic regulation of molecular chaperone gene expression in polyglutamine disease. Biochem. Biophys. Res. Commun. 2005, 334:1074-1084.
85. Ichikawa Y., Goto J., Hattori M., Toyoda A., Ishii K., Jeong S.Y., Hashida H., Masuda N., Ogata K., Kasai F., Hirai M., Maciel P., Rouleau G.A., Sakaki Y., Kanazawa I. The genomic structure and expression of MJD, the Machado-Joseph disease gene. J. Hum. Genet. 2001, 46:413-422.
86. Igarashi S., Takiyama Y., Cancel G., Rogaeva E.A., Sasaki H., Wakisaka A., Zhou Y.X., Takano H., Endo K., Sanpei K., Oyake M., Tanaka H., Stevanin G., Abbas N., Durr A., Rogaev E.I., Sherrington R., Tsuda T., Ikeda M., Cassa E., Nishizawa M., Benomar A., Julien J., Weissenbach J., Wang G.X., Agid Y., St George-Hyslop P.H., Brice A., Tsuji S. Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications for the molecular mechanisms of the instability of the CAG repeat. Hum. Mol. Genet. 1996, 5:923-932.
87. Ikeda H., Yamaguchi M., Sugai S., Aze Y., Narumiya S., Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 1996, 13:196-202.
88. Iwabuchi K., Tsuchiya K., Uchihara T., Yagishita S. Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. Rev. Neurol. (Paris) 1999, 155:255-270.
89. Jana N.R., Dikshit P., Goswami A., Kotliarova S., Murata S., Tanaka K., Nukina N. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 2005, 280:11635-11640.
90. Jardim L.B., Pereira M.L., Silveira I., Ferro A., Sequeiros J., Giugliani R. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG)n. Arch. Neurol. 2001, 58:899-904.
91. Jeub M., Herbst M., Spauschus A., Fleischer H., Klockgether T., Wuellner U., Evert B.O. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3. Exp. Neurol. 2006, 201:182-192.
92. Jung J., Xu K., Lessing D., Bonini N.M. Preventing ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum. Mol. Genet. 2009, 18:4843-4852.
93. Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M., Katayama S., Kawakami H., Nakamura S., Nishimura M., Akiguchi I., et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 1994, 8:221-228.
94. Kawai Y., Takeda A., Abe Y., Washimi Y., Tanaka F., Sobue G. Cognitive impairments in Machado-Joseph disease. Arch. Neurol. 2004, 61:1757-1760.
95. Khan L.A., Bauer P.O., Miyazaki H., Lindenberg K.S., Landwehrmeyer B.G., Nukina N. Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. J. Neurochem. 2006, 98:576-587.
96. Klockgether T., Skalej M., Wedekind D., Luft A.R., Welte D., Schulz J.B., Abele M., Burk K., Laccone F., Brice A., Dichgans J. Autosomal dominant cerebellar ataxia type I, MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 1998, 121(Pt 9):1687-1693.
97. Kremer E.J., Pritchard M., Lynch M., Yu S., Holman K., Baker E., Warren S.T., Schlessinger D., Sutherland G.R., Richards R.I. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 1991, 252:1711-1714.
98. Kobayashi T., Tanaka K., Inoue K., Kakizuka A. Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells. J. Biol. Chem. 2002, 277:47358-47365.
99. Kuhlbrodt K., Janiesch P.C., Kevei E., Segref A., Barikbin R., Hoppe T. The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat. Cell. Biol. 2011, 13:273-281.
100. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
101. LaLonde D.P., Bretscher A. The UBX protein SAKS1 negatively regulates endoplasmic reticulum-associated degradation and p97-dependent degradation. J. Biol. Chem. 2011, 286:4892-4901.
102. Landau W.M., Schmidt R.E., McGlennen R.C., Reich S.G. Hereditary spastic paraplegia and hereditary ataxia, Part 2: A family demonstrating various phenotypic manifestations with the SCA3 genotype. Arch. Neurol. 2000, 57:733-739.
103. Lang A.E., Rogaeva E.A., Tsuda T., Hutterer J., St George-Hyslop P. Homozygous inheritance of the Machado-Joseph disease gene. Ann. Neurol. 1994, 36:443-447.
104. Lerer I., Merims D., Abeliovich D., Zlotogora J., Gadoth N. Machado-Joseph disease: correlation between the clinical features, the CAG repeat length and homozygosity for the mutation. Eur. J. Hum. Genet. 1996, 4:3-7.
105. Lessing D., Bonini N.M. Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biol 2008, 6:e29.
106. Li F., Macfarlan T., Pittman R.N., Chakravarti D. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 2002, 277:45004-45012.
107. Li L.B., Xu K., Bonini N.M. Suppression of polyglutamine toxicity by the yeast Sup35 prion domain in Drosophila. J. Biol. Chem. 2007, 282:37694-37701.
108. Li L.B., Yu Z., Teng X., Bonini N.M. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 2008, 453:1107-1111.
109. Lim J., Crespo-Barreto J., Jafar-Nejad P., Bowman A.B., Richman R., Hill D.E., Orr H.T., Zoghbi H.Y. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452:713-718.
110. Lim J., Hao T., Shaw C., Patel A.J., Szabo G., Rual J.F., Fisk C.J., Li N., Smolyar A., Hill D.E., Barabasi A.L., Vidal M., Zoghbi H.Y. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 2006, 125:801-814.
111. Lima L., Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family. Neurology 1980, 30:319-322.
112. Lima M., Costa M.C., Montiel R., Ferro A., Santos C., Silva C., Bettencourt C., Sousa A., Sequeiros J., Coutinho P., Maciel P. Population genetics of wild-type CAG repeats in the Machado-Joseph disease gene in Portugal. Hum. Hered. 2005, 60:156-163.
113. Lima M., Kay T., Vasconcelos J., Mota-Vieira L., Gonzalez C., Peixoto A., Abade A., MacLeod P., Graca R., Santos J. Disease knowledge and attitudes toward predictive testing and prenatal diagnosis in families with Machado-Joseph disease from the Azores Islands (Portugal). Community Genet. 2001, 4:36-42.
114. Lindblad K., Lunkes A., Maciel P., Stevanin G., Zander C., Klockgether T., Ratzlaff T., Brice A., Rouleau G.A., Hudson T., Auburger G., Schalling M. Mutation detection in Machado-Joseph disease using repeat expansion detection. Mol. Med. 1996, 2:77-85.
115. Linhartova I., Repitz M., Draber P., Nemec M., Wiche G., Propst F. Conserved domains and lack of evidence for polyglutamine length polymorphism in the chicken homolog of the Machado-Joseph disease gene product ataxin-3. Biochim. Biophys. Acta 1999, 1444:299-305.
116. Livingstone I.R., Sequeiros J. Machado-Joseph disease in an American-Italian family. J. Neurogenet. 1984, 1:185-188.
117. Lopes-Cendes I., Maciel P., Kish S., Gaspar C., Robitaille Y., Clark H.B., Koeppen A.H., Nance M., Schut L., Silveira I., Coutinho P., Sequeiros J., Rouleau G.A. Somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and Machado-Joseph disease. Ann. Neurol. 1996, 40:199-206.
118. Macedo-Ribeiro S., Cortes L., Maciel P., Carvalho A.L. Nucleocytoplasmic shuttling activity of ataxin-3. PLoS One 2009, 4:e5834.
119. Maciel P., Costa M.C., Ferro A., Rousseau M., Santos C.S., Gaspar C., Barros J., Rouleau G.A., Coutinho P., Sequeiros J. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch. Neurol. 2001, 58:1821-1827.
120. Maciel P., Gaspar C., DeStefano A.L., Silveira I., Coutinho P., Radvany J., Dawson D.M., Sudarsky L., Guimaraes J., Loureiro J.E., et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am. J. Hum. Genet. 1995, 57:54-61.
121. Maciel P., Gaspar C., Guimaraes L., Goto J., Lopes-Cendes I., Hayes S., Arvidsson K., Dias A., Sequeiros J., Sousa A., Rouleau G.A. Study of three intragenic polymorphisms in the Machado-Joseph disease gene (MJD1) in relation to genetic instability of the (CAG)n tract. Eur. J. Hum. Genet. 1999, 7:147-156.
122. Maciel P., Lopes-Cendes I., Kish S., Sequeiros J., Rouleau G.A. Mosaicism of the CAG repeat in CNS tissue in relation to age at death in spinocerebellar ataxia type 1 and Machado-Joseph disease patients. Am. J. Hum. Genet. 1997, 60:993-996.
123. Mao Y., Senic-Matuglia F., Di Fiore P.P., Polo S., Hodsdon M.E., De Camilli P. Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12700-12705.
124. Margolis R.L. The spinocerebellar ataxias: order emerges from chaos. Curr. Neurol. Neurosci. Rep. 2002, 2:447-456.
125. Martins S., Calafell F., Gaspar C., Wong V.C., Silveira I., Nicholson G.A., Brunt E.R., Tranebjaerg L., Stevanin G., Hsieh M., Soong B.W., Loureiro L., Durr A., Tsuji S., Watanabe M., Jardim L.B., Giunti P., Riess O., Ranum L.P., Brice A., Rouleau G.A., Coutinho P., Amorim A., Sequeiros J. Asian origin for the worldwide-spread mutational event in Machado-Joseph disease. Arch. Neurol. 2007, 64:1502-1508.
126. Martins S., Calafell F., Wong V.C., Sequeiros J., Amorim A. A multistep mutation mechanism drives the evolution of the CAG repeat at MJD/SCA3 locus. Eur. J. Hum. Genet. 2006, 14:932-940.
127. Martins S., Coutinho P., Silveira I., Giunti P., Jardim L.B., Calafell F., Sequeiros J., Amorim A. Cis-acting factors promoting the CAG intergenerational instability in Machado-Joseph disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:439-446.
128. Maruyama H., Nakamura S., Matsuyama Z., Sakai T., Doyu M., Sobue G., Seto M., Tsujihata M., Oh-i T., Nishio T., et al. Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease. Hum. Mol. Genet. 1995, 4:807-812.
129. Masino L., Musi V., Menon R.P., Fusi P., Kelly G., Frenkiel T.A., Trottier Y., Pastore A. Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett. 2003, 549:21-25.
130. Masino L., Nicastro G., Calder L., Vendruscolo M., Pastore A. Functional interactions as a survival strategy against abnormal aggregation. FASEB J. 2011, 25:45-54.
131. Masino L., Nicastro G., De Simone A., Calder L., Molloy J., Pastore A. The Josephin domain determines the morphological and mechanical properties of ataxin-3 fibrils. Biophys. J. 2011, 100:2033-2042.
132. Matilla T., McCall A., Subramony S.H., Zoghbi H.Y. Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. Ann. Neurol. 1995, 38:68-72.
133. Matos C.A., de Macedo-Ribeiro S., Carvalho A.L. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Prog. Neurobiol. 2011, 95:26-48.
134. Matsumoto M., Yada M., Hatakeyama S., Ishimoto H., Tanimura T., Tsuji S., Kakizuka A., Kitagawa M., Nakayama K.I. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J. 2004, 23:659-669.
135. Mauri P.L., Riva M., Ambu D., De Palma A., Secundo F., Benazzi L., Valtorta M., Tortora P., Fusi P. Ataxin-3 is subject to autolytic cleavage. FEBS J. 2006, 273:4277-4286.
136. Mazzucchelli S., De Palma A., Riva M., D'Urzo A., Pozzi C., Pastori V., Comelli F., Fusi P., Vanoni M., Tortora P., Mauri P., Regonesi M.E. Proteomic and biochemical analyses unveil tight interaction of ataxin-3 with tubulin. Int. J. Biochem. Cell Biol. 2009, 41:2485-2492.
137. Menzies F.M., Huebener J., Renna M., Bonin M., Riess O., Rubinsztein D.C. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 2010, 133:93-104.
138. Mishra A., Dikshit P., Purkayastha S., Sharma J., Nukina N., Jana N.R. E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J. Biol. Chem. 2008, 283:7648-7656.
139. Mori F., Nishie M., Piao Y.S., Kito K., Kamitani T., Takahashi H., Wakabayashi K. Accumulation of NEDD8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 2005, 31:53-61.
140. Mueller T., Breuer P., Schmitt I., Walter J., Evert B.O., Wullner U. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. 2009, 18:3334-3343.
141. Murata Y., Yamaguchi S., Kawakami H., Imon Y., Maruyama H., Sakai T., Kazuta T., Ohtake T., Nishimura M., Saida T., Chiba S., Oh-i T., Nakamura S. Characteristic magnetic resonance imaging findings in Machado-Joseph disease. Arch. Neurol. 1998, 55:33-37.
142. Nagai Y., Inui T., Popiel H.A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H., Toda T. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 2007, 14:332-340.
143. Nakano K.K., Dawson D.M., Spence A. Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology 1972, 22:49-55.
144. Nascimento-Ferreira I., Santos-Ferreira T., Sousa-Ferreira L., Auregan G., Onofre I., Alves S., Dufour N., Colomer Gould V.F., Koeppen A., Deglon N., Pereira de Almeida L. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain 2011, 134:1400-1415.
145. Natalello A., Frana A.M., Relini A., Apicella A., Invernizzi G., Casari C., Gliozzi A., Doglia S.M., Tortora P., Regonesi M.E. A major role for side-chain polyglutamine hydrogen bonding in irreversible ataxin-3 aggregation. PLoS One 2011, 6:e18789.
146. Nicastro G., Habeck M., Masino L., Svergun D.I., Pastore A. Structure validation of the Josephin domain of ataxin-3: conclusive evidence for an open conformation. J. Biomol. NMR 2006, 36:267-277.
147. Nicastro G., Masino L., Esposito V., Menon R.P., De Simone A., Fraternali F., Pastore A. Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites. Biopolymers 2009, 91:1203-1214.
148. Nicastro G., Menon R.P., Masino L., Knowles P.P., McDonald N.Q., Pastore A. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10493-10498.
149. Nicastro G., Todi S.V., Karaca E., Bonvin A.M., Paulson H.L., Pastore A. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. PLoS One 2010, 5:e12430.
150. Onodera O., Idezuka J., Igarashi S., Takiyama Y., Endo K., Takano H., Oyake M., Tanaka H., Inuzuka T., Hayashi T., Yuasa T., Ito J., Miyatake T., Tsuji S. Progressive atrophy of cerebellum and brainstem as a function of age and the size of the expanded CAG repeats in the MJD1 gene in Machado-Joseph disease. Ann. Neurol. 1998, 43:288-296.
151. Padiath Q.S., Srivastava A.K., Roy S., Jain S., Brahmachari S.K. Identification of a novel 45 repeat unstable allele associated with a disease phenotype at the MJD1/SCA3 locus. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 133B:124-126.
152. Paulson H. Spinocerebellar ataxia type 3. GeneReviews [Internet] 1998 Oct 10, University of Washington, Seattle (WA), [updated 2011 March 17]. R.A. Pagon, C.R. Dolan, K. Stephens (Eds.).
153. Paulson H.L. Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3. Semin. Neurol. 2007, 27:133-142.
154. Paulson H.L., Das S.S., Crino P.B., Perez M.K., Patel S.C., Gotsdiner D., Fischbeck K.H., Pittman R.N. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 1997, 41:453-462.
155. Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., Vig P., Mandel J.L., Fischbeck K.H., Pittman R.N. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997, 19:333-344.
156. Perez M.K., Paulson H.L., Pendse S.J., Saionz S.J., Bonini N.M., Pittman R.N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 1998, 143:1457-1470.
157. Perutz M.F., Finch J.T., Berriman J., Lesk A. Amyloid fibers are water-filled nanotubes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:5591-5595.
158. Pozzi C., Valtorta M., Tedeschi G., Galbusera E., Pastori V., Bigi A., Nonnis S., Grassi E., Fusi P. Study of subcellular localization and proteolysis of ataxin-3. Neurobiol. Dis. 2008, 30:190-200.
159. Reina C.P., Zhong X., Pittman R.N. Proteotoxic stress increases nuclear localization of ataxin-3. Hum. Mol. Genet. 2010, 19:235-249.
160. Riess O., Rub U., Pastore A., Bauer P., Schols L. SCA3: neurological features, pathogenesis and animal models. Cerebellum 2008, 7:125-137.
161. Robertson A.L., Headey S.J., Saunders H.M., Ecroyd H., Scanlon M.J., Carver J.A., Bottomley S.P. Small heat-shock proteins interact with a flanking domain to suppress polyglutamine aggregation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10424-10429.
162. Rodrigues A.J., Coppola G., Santos C., Costa M.C., Ailion M., Sequeiros J., Geschwind D.H., Maciel P. Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado-Joseph disease protein ataxin-3. FASEB J. 2007, 21:1126-1136.
163. Rodrigues A.J., Neves-Carvalho A., Ferro A., Rokka A., Corthals G., Logarinho E., Maciel P. ATX-3, CDC-48 and UBXN-5: a new trimolecular complex in C. elegans. Biochem. Biophys. Res. Commun. 2009, 386:575-581.
164. Rodrigues A.J., do Carmo Costa M., Silva T.L., Ferreira D., Bajanca F., Logarinho E., Maciel P. Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death. Biochim. Biophys. Acta 2010, 1803:1154-1163.
165. Rodrigues A.J., Neves-Carvalho A., Teixeira-Castro A., Rokka A., Corthals G., Logarinho E., Maciel P. Absence of ataxin-3 leads to enhanced stress response in C. elegans. PLoS One 2011, 6:e18512.
166. Rolim L., Leite A., Ledo S., Paneque M., Sequeiros J., Fleming M. Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I. Clin. Genet. 2006, 69:297-305.
167. Romanul F.C., Fowler H.L., Radvany J., Feldman R.G., Feingold M. Azorean disease of the nervous system. N. Engl. J. Med. 1977, 296:1505-1508.
168. Rosenberg R.N. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov. Disord. 1992, 7:193-203.
169. Rosenberg R.N., Nyhan W.L., Bay C., Shore P. Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology 1976, 26:703-714.
170. Ross C.A. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 1995, 15:493-496.
171. Rub U., Brunt E.R., Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr. Opin. Neurol. 2008, 21:111-116.
172. Rüb U., de Vos R.A., Brunt E.R., Sebesteny T., Schols L., Auburger G., Bohl J., Ghebremedhin E., Gierga K., Seidel K., den Dunnen W., Heinsen H., Paulson H., Deller T. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol. 2006, 16:218-227.
173. Rub U., Seidel K., Ozerden I., Gierga K., Brunt E.R., Schols L., de Vos R.A., den Dunnen W., Schultz C., Auburger G., Deller T. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res. Brain Res. Rev. 2007, 53:235-249.
174. Sakai T., Kawakami H. Machado-Joseph disease: a proposal of spastic paraplegic subtype. Neurology 1996, 46:846-847.
175. Sakai T., Ohta M., Ishino H. Joseph disease in a non-Portuguese family. Neurology 1983, 33:74-80.
176. Saunders H.M., Gilis D., Rooman M., Dehouck Y., Robertson A.L., Bottomley S.P. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein. Protein Sci. 2011, 20:1675-1681.
177. Scaglione K.M., Zavodszky E., Todi S.V., Patury S., Xu P., Rodriguez-Lebron E., Fischer S., Konen J., Djarmati A., Peng J., Gestwicki J.E., Paulson H.L. Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol. Cell 2011, 43:599-612.
178. Scheel H., Tomiuk S., Hofmann K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum. Mol. Genet. 2003, 12:2845-2852.
179. Schmidt T., Landwehrmeyer G.B., Schmitt I., Trottier Y., Auburger G., Laccone F., Klockgether T., Volpel M., Epplen J.T., Schols L., Riess O. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998, 8:669-679.
180. Schmitt I., Brattig T., Gossen M., Riess O. Characterization of the rat spinocerebellar ataxia type 3 gene. Neurogenetics 1997, 1:103-112.
181. Schmitt I., Evert B.O., Khazneh H., Klockgether T., Wuellner U. The human MJD gene: genomic structure and functional characterization of the promoter region. Gene 2003, 314:81-88.
182. Schmitt I., Linden M., Khazneh H., Evert B.O., Breuer P., Klockgether T., Wuellner U. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem. Biophys. Res. Commun. 2007, 362:734-739.
183. Schols L., Amoiridis G., Epplen J.T., Langkafel M., Przuntek H., Riess O. Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation. J. Neurol. Neurosurg. Psychiatry 1996, 61:466-470.
184. Schols L., Bauer P., Schmidt T., Schulte T., Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004, 3:291-304.
185. Seidel K., den Dunnen W.F., Schultz C., Paulson H., Frank S., de Vos R.A., Brunt E.R., Deller T., Kampinga H.H., Rub U. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol. 2010, 120:449-460.
186. Sequeiros J., Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. Adv. Neurol. 1993, 61:139-153.
187. Sequeiros J., Maciel P., Taborda F., Ledo S., Rocha J.C., Lopes A., Reto F., Fortuna A.M., Rousseau M., Fleming M., Coutinho P., Rouleau G.A., Jorge C.S. Prenatal diagnosis of Machado-Joseph disease by direct mutation analysis. Prenat. Diagn. 1998, 18:611-617.
188. Sequeiros J., Suite N.D. Spinopontine atrophy disputed as a separate entity: the first description of Machado-Joseph disease. Neurology 1986, 36:1408.
189. Shakkottai V.G., do Carmo Costa M., Dell'orco J.M., Sankaranarayanan A., Wulff H., Paulson H.L. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J. Neurosci. 2011, 31:13002-13014.
190. Shen L., Tang B.S., Tang J.G., Jiang H., Wang C., Fang H.Y. [Screening for proteins interacting with ataxin-3, the gene product of SCA3/MJD]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006, 31:40-44.
191. Sikorski P., Atkins E. New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules 2005, 6:425-432.
192. Silva-Fernandes A., Costa Mdo C., Duarte-Silva S., Oliveira P., Botelho C.M., Martins L., Mariz J.A., Ferreira T., Ribeiro F., Correia-Neves M., Costa C., Maciel P. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol. Dis. 2010, 40:163-176.
193. Sobue G., Doyu M., Nakao N., Shimada N., Mitsuma T., Maruyama H., Kawakami S., Nakamura S. Homozygosity for Machado-Joseph disease gene enhances phenotypic severity. J. Neurol. Neurosurg. Psychiatry 1996, 60:354-356.
194. Soong B.W., Liu R.S. Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease. J. Neurol. Neurosurg. Psychiatry 1998, 64:499-504.
195. Sowa M.E., Bennett E.J., Gygi S.P., Harper J.W. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009, 138:389-403.
196. Sugiura A., Yonashiro R., Fukuda T., Matsushita N., Nagashima S., Inatome R., Yanagi S. A mitochondrial ubiquitin ligase MITOL controls cell toxicity of polyglutamine-expanded protein. Mitochondrion 2010, 11:139-146.
197. Tait D., Riccio M., Sittler A., Scherzinger E., Santi S., Ognibene A., Maraldi N.M., Lehrach H., Wanker E.E. Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum. Mol. Genet. 1998, 7:991-997.
198. Takahashi J., Tanaka J., Arai K., Funata N., Hattori T., Fukuda T., Fujigasaki H., Uchihara T. Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease. J. Neuropathol. Exp. Neurol. 2001, 60:369-376.
199. Takeshita Y., Fujinaga R., Kokubu K., Islam M.N., Jahan M.R., Yanai A., Kakizuka A., Shinoda K. Interaction of ataxin-3 with huntingtin-associated protein 1 through Josephin domain. Neuroreport 2011, 22:232-238.
200. Takiyama Y., Igarashi S., Rogaeva E.A., Endo K., Rogaev E.I., Tanaka H., Sherrington R., Sanpei K., Liang Y., Saito M., et al. Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum. Mol. Genet. 1995, 4:1137-1146.
201. Takiyama Y., Nishizawa M., Tanaka H., Kawashima S., Sakamoto H., Karube Y., Shimazaki H., Soutome M., Endo K., Ohta S., et al. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat. Genet. 1993, 4:300-304.
202. Takiyama Y., Sakoe K., Nakano I., Nishizawa M. Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Neurology 1997, 49:604-606.
203. Taniguchi R., Konigsmark B.W. Dominant spino-pontine atrophy. Report of a family through three generations. Brain 1971, 94:349-358.
204. Taniwaki T., Sakai T., Kobayashi T., Kuwabara Y., Otsuka M., Ichiya Y., Masuda K., Goto I. Positron emission tomography (PET) in Machado-Joseph disease. J. Neurol. Sci. 1997, 145:63-67.
205. Tao R.S., Fei E.K., Ying Z., Wang H.F., Wang G.H. Casein kinase 2 interacts with and phosphorylates ataxin-3. Neurosci. Bull. 2008, 24:271-277.
206. Teixeira-Castro A., Ailion M., Jalles A., Brignull H.R., Vilaca J.L., Dias N., Rodrigues P., Oliveira J.F., Neves-Carvalho A., Morimoto R.I., Maciel P. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum. Mol. Genet. 2011, 20:2996-3009.
207. Todi S.V., Laco M.N., Winborn B.J., Travis S.M., Wen H.M., Paulson H.L. Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity. J. Biol. Chem. 2007, 282:29348-29358.
208. Todi S.V., Paulson H.L. Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci. 2011, 34:370-382.
209. Todi S.V., Scaglione K.M., Blount J.R., Basrur V., Conlon K.P., Pastore A., Elenitoba-Johnson K., Paulson H.L. Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117. J. Biol. Chem. 2010, 285:39303-39313.
210. Todi S.V., Winborn B.J., Scaglione K.M., Blount J.R., Travis S.M., Paulson H.L. Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J. 2009, 28:372-382.
211. Torashima T., Koyama C., Iizuka A., Mitsumura K., Takayama K., Yanagi S., Oue M., Yamaguchi H., Hirai H. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep. 2008, 9:393-399.
212. Tower C., Fu L., Gill R., Prichard M., Lesort M., Sztul E. Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia. Neurobiol. Dis. 2011, 41:11-22.
213. Trottier Y., Cancel G., An-Gourfinkel I., Lutz Y., Weber C., Brice A., Hirsch E., Mandel J.L. Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol. Dis. 1998, 5:335-347.
214. Tsai H.F., Tsai H.J., Hsieh M. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells. Biochem. Biophys. Res. Commun. 2004, 324:1274-1282.
215. Tsai Y.C., Fishman P.S., Thakor N.V., Oyler G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 2003, 278:22044-22055.
216. van Alfen N., Sinke R.J., Zwarts M.J., Gabreels-Festen A., Praamstra P., Kremer B.P., Horstink M.W. Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype. Ann. Neurol. 2001, 49:805-807.
217. van Schaik I.N., Jobsis G.J., Vermeulen M., Keizers H., Bolhuis P.A., de Visser M. Machado-Joseph disease presenting as severe asymmetric proximal neuropathy. J. Neurol. Neurosurg. Psychiatry 1997, 63:534-536.
218. Wang G., Ide K., Nukina N., Goto J., Ichikawa Y., Uchida K., Sakamoto T., Kanazawa I. Machado-Joseph disease gene product identified in lymphocytes and brain. Biochem. Biophys. Res. Commun. 1997, 233:476-479.
219. Wang G., Sawai N., Kotliarova S., Kanazawa I., Nukina N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum. Mol. Genet. 2000, 9:1795-1803.
220. Wang H., Jia N., Fei E., Wang Z., Liu C., Zhang T., Fan J., Wu M., Chen L., Nukina N., Zhou J., Wang G. p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin-3 to the proteasome. J. Neurochem. 2007, 101:1651-1661.
221. Wang Q., Li L., Ye Y. Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3. J. Cell Biol. 2006, 174:963-971.
222. Wang Y.G., Du J., Wang J.L., Chen J., Chen C., Luo Y.Y., Xiao Z.Q., Jiang H., Yan X.X., Xia K., Pan Q., Tang B.S., Shen L. Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic. J. Neurol. Sci. 2009, 285:121-124.
223. Warrick J.M., Morabito L.M., Bilen J., Gordesky-Gold B., Faust L.Z., Paulson H.L., Bonini N.M. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell 2005, 18:37-48.
224. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 1999, 23:425-428.
225. Warrick J.M., Paulson H.L., Gray-Board G.L., Bui Q.T., Fischbeck K.H., Pittman R.N., Bonini N.M. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998, 93:939-949.
226. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 1998, 273:9158-9167.
227. Williams A.J., Paulson H.L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008, 31:521-528.
228. Williams A.J., Knutson T.M., Colomer Gould V.F., Paulson H.L. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol. Dis. 2009, 33:342-353.
229. Winborn B.J., Travis S.M., Todi S.V., Scaglione K.M., Xu P., Williams A.J., Cohen R.E., Peng J., Paulson H.L. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J. Biol. Chem. 2008, 283:26436-26443.
230. Woelk T., Sigismund S., Penengo L., Polo S. The ubiquitination code: a signalling problem. Cell. Div. 2007, 2:11.
231. Woods B.T., Schaumburg H.H. Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J. Neurol. Sci. 1972, 17:149-166.
232. Wullner U., Reimold M., Abele M., Burk K., Minnerop M., Dohmen B.M., Machulla H.J., Bares R., Klockgether T. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch. Neurol. 2005, 62:1280-1285.
233. Yamada M., Sato T., Tsuji S., Takahashi H. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:71-86.
234. Yamada M., Tan C.F., Inenaga C., Tsuji S., Takahashi H. Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases. Neuropathol. Appl. Neurobiol. 2004, 30:665-675.
235. Yamada M., Tsuji S., Takahashi H. Involvement of lysosomes in the pathogenesis of CAG repeat diseases. Ann. Neurol. 2002, 52:498-503.
236. Ying Z., Wang H., Fan H., Zhu X., Zhou J., Fei E., Wang G. Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum. Mol. Genet. 2009, 18:4268-4281.
237. Yoshizawa T., Watanabe M., Frusho K., Shoji S. Magnetic resonance imaging demonstrates differential atrophy of pontine base and tegmentum in Machado-Joseph disease. J. Neurol. Sci. 2003, 215:45-50.
238. Yu Y.C., Kuo C.L., Cheng W.L., Liu C.S., Hsieh M. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J. Neurosci. Res. 2009, 87:1884-1891.
239. Zhong X., Pittman R.N. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates. Hum. Mol. Genet. 2006, 15:2409-2420.
240. Zoghbi H.Y., Orr H.T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 2009, 284:7425-7429.